News | April 16, 2014

Covidien Implements Voluntary Recall of its Pipeline Embolization Device and Alligator Retrieval Device

April 16, 2014 — Covidien announced it has notified customers of a voluntary recall to address an issue with certain lots of its Pipeline embolization device and Alligator retrieval device, where the polytetrafluoroethylene (PTFE) coating applied to the delivery wire could delaminate and detach from the devices.

PTFE coating is used to reduce friction between devices and ease navigation through the vasculature. Delamination of the PTFE coating could potentially lead to embolic occlusion in the cerebral vasculature with the risk of stroke and/or death.

Covidien learned of this issue through internal product testing. The company has not received any reports of patient injuries to date related to this issue.

The Pipeline embolization device is indicated for the endovascular treatment of adults (22 years of age and older) with large or giant wide?necked intracranial aneurysms in the internal carotid artery from the petrous to the superior hypophyseal segments. The Alligator retrieval device is intended for use in the peripheral and neuro?vasculature for foreign body retrieval.

A total of 32 Pipeline embolization devices and 621 Alligator retrieval devices are affected by this recall. The products were manufactured and distributed from May 2013 to March 2014. This issue involves both the Pipeline embolization device sold in the United States, Australia, France, Germany and United Kingdom, and the Alligator retrieval device sold in the United States, Australia, Canada, Europe and Latin America.

Covidien alerted customers to the recall by letter on April 1, 2014, and is arranging for replacement of the recalled products. The U.S. Food and Drug Administration (FDA) and other regulatory bodies also have been notified.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

For more information: www.covidien.com


Related Content

News | Stroke

March 5, 2024 — Frequent cannabis smoking may significantly increase a person’s risk for heart attack and stroke ...

Home March 05, 2024
Home
News | Stroke

March 5, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 05, 2024
Home
News | Stroke

February 26, 2024 — Ischemic strokes are a major health burden. They occur when a blood vessel that supplies the brain ...

Home February 26, 2024
Home
News | Stroke

February 15, 2024 — Research findings in a clinical trial led by a professor at the University of Tennessee Health ...

Home February 15, 2024
Home
News | Stroke

February 13, 2024 — RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow ...

Home February 13, 2024
Home
News | Stroke

February 12, 2024 — VST Bio Corp. a leader in the development of innovative biologics to treat acute and chronic ...

Home February 12, 2024
Home
News | Stroke

February 9, 2024 — MIVI Neuroscience, Inc. announced the primary endpoint results of its EvaQ Trial, a prospective ...

Home February 09, 2024
Home
News | Stroke

February 7, 2024 — Medtronic announced new cost-effectiveness data from the STROKE AF clinical study, which showed that ...

Home February 07, 2024
Home
News | Stroke

February 7, 2024 — Combining brain stimulation with intense physical rehabilitation helped stroke survivors recover ...

Home February 07, 2024
Home
News | Stroke

January 15, 2024 — Larry Goldstein, M.D., chair of the University of Kentucky Department of Neurology, has been selected ...

Home January 15, 2024
Home
Subscribe Now